Reactions 1680, p68 - 2 Dec 2017 Aggravation of cerebral radiation necrosis: case report In a study, a 53-year-old woman was described who developed aggravation of cerebral radiation necrosis (CRN) following the administration of bevacizumab [route not stated]. The woman with a history of brain metastasis of lung adenocarcinoma was treated with stereotactic radiotherapy. She was diagnosed with CRN in September 2012. From December 2012 to July 2013, she received 10 cycles of bevacizumab. During the treatment, her condition had resolved markedly. Nonetheless, in June 2014, the CRN recurred. From October 2014 to March 2015, she was scheduled to receive seven cycles of bevacizumab 5 mg/kg every three to four weeks. In March 2015, a re-examination demonstrated aggravation of CRN instead of reduction. The woman’s treatment with bevacizumab was discontinued. In September 2015, the CRN exhibited local resolution and dissipation. Author comment: "Long time bevacizumab medications cause blood vessels over trimming, and the CRN aggravation." "The lesion was significantly reduced after discontinuation." Zhuang H, et al. Indication of bevacizumab for cerebral radiation necrosis. Recent Patents on Anti-Cancer Drug Discovery 12: 272-277, No. 3, 2017. Available from: URL: http://doi.org/10.2174/1574892812666170425124430 - China 803285422 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera